title: How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
abstract: Although the central role of 1p/19q codeletion in oligodendroglioma was established almost two decades ago, apart from clear prognostic significance the implications for clinical care have been less clear. This has changed with the long-term follow-up analysis of the EORTC and RTOG trials on procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma. These have shown that 1p/19q loss in these tumors is predictive of overall survival benefit of the addition of PCV chemotherapy to radiotherapy.
authors.affiliation: From the Department of Neuro-oncology, ErasmusMC-Cancer Institute, Rotterdam, Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: van den Bent
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000235:genetics* / Q000628:therapy; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics*; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics*; D018572:Disease-Free Survival; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D009837:Oligodendroglioma / Q000235:genetics* / Q000628:therapy; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D011878:Radiotherapy; D014178:Translocation, Genetic; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine